Matthew R. Cheetham
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Matthew R. Cheetham has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- David Klenerman
University of Cambridge
4 shared publications - Jeff Y. L. Lam
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UK
2 shared publications - Andrey S. Klymchenko
Université de Strasbourg, CNRS
1 shared publication - Christopher A. Hunter
Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, CB2 1EW, UK
1 shared publication David P. Marshall
Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Oxford OX1 3TA, United Kingdom
1 shared publication- Dorothea Böken
University of Cambridge
1 shared publication
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (64) , e77453
Tau Aggregate Imaging and Transcriptomics of Alzheimer's Disease Brain at Different Stages of Disease
Tau aggregation plays a critical role in the development and progression of Alzheimer's disease (AD). Tau aggregates of different sizes and shapes are formed, which ultimately lead to the deposition of fibrillar tangles. We used single‐molecule techniques to characterize tau aggregates in the middle temporal gyrus and somatosensory cortex in post‐mortem brain homogenates at different Braak stages from patients with AD. Total and phosphorylated tau aggregates increased dramatically in late Braak stages. The aggregates showed greater multi‐site phosphorylation with increased Braak stage, but there was only a moderate change in the aggregate size distribution. Paired single nuclei transcriptomic analyses provided evidence for greater pro‐inflammatory microglial and complement pathway activation with increasing phosphorylated tau aggregate concentration and length. Based on this correlation, we hypothesize a cascade of disease progression in which microglial inflammation induces tau aggregation in neighboring neurons that, in turn, further enhances inflammation and the spread of tau pathology to increase the concentration of small tau aggregates.
- 31 August 2026
- Published by Wiley in Advanced Science
- Vol. 13 (64) , e77453
Open AccessTau Aggregate Imaging and Transcriptomics of Alzheimer's Disease Brain at Different Stages of Disease
Tau aggregation plays a critical role in the development and progression of Alzheimer's disease (AD). Tau aggregates of different sizes and shapes are formed, which ultimately lead to the deposition of fibrillar tangles. We used single‐molecule techniques to characterize tau aggregates in the middle temporal gyrus and somatosensory cortex in post‐mortem brain homogenates at different Braak stages from patients with AD. Total and phosphorylated tau aggregates increased dramatically in late Braak stages. The aggregates showed greater multi‐site phosphorylation with increased Braak stage, but there was only a moderate change in the aggregate size distribution. Paired single nuclei transcriptomic analyses provided evidence for greater pro‐inflammatory microglial and complement pathway activation with increasing phosphorylated tau aggregate concentration and length. Based on this correlation, we hypothesize a cascade of disease progression in which microglial inflammation induces tau aggregation in neighboring neurons that, in turn, further enhances inflammation and the spread of tau pathology to increase the concentration of small tau aggregates.
- Open Access
- 16 June 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (29) , 13435-13448
Detecting alpha-synuclein aggregates with small molecules on single-molecule array
Protein aggregates are promising biomarkers for early diagnosis of neurodegenerative disorders. Single-Molecule Array (SiMoA) is a powerful method to detect these aggregates at ultra-low concentrations in biofluids. Herein, we report a next-generation SiMoA assay using chemically synthesized small molecules, rather than antibodies, to capture alpha-synuclein aggregates, a protein hallmark in Parkinson's Disease and other synucleinopathies. These small molecule-based capturing agents contain aggregate-binding head groups, and a backbone functionalized with a primary amine for bead conjugation in the SiMoA assay. The most promising molecule, BF-79-2, captured recombinant alpha-synuclein aggregates, specifically excluding monomers, at picomolar concentrations. BF-79-2 also captured alpha-synuclein aggregates in human blood. Replacing antibodies with small molecules as capturing agents on the SiMoA platform enhances the assay versatility, since small molecules can be screened in silico and synthesized without laborious molecular biology techniques. The application of small molecules as capturing agents broadens the capabilities of the SiMoA platform, rendering it more adaptable for biomarker discovery and disease diagnostics.
- 16 June 2025
- Published by Royal Society of Chemistry (RSC) in Chemical Science
- Vol. 16 (29) , 13435-13448
Open AccessDetecting alpha-synuclein aggregates with small molecules on single-molecule array
Protein aggregates are promising biomarkers for early diagnosis of neurodegenerative disorders. Single-Molecule Array (SiMoA) is a powerful method to detect these aggregates at ultra-low concentrations in biofluids. Herein, we report a next-generation SiMoA assay using chemically synthesized small molecules, rather than antibodies, to capture alpha-synuclein aggregates, a protein hallmark in Parkinson's Disease and other synucleinopathies. These small molecule-based capturing agents contain aggregate-binding head groups, and a backbone functionalized with a primary amine for bead conjugation in the SiMoA assay. The most promising molecule, BF-79-2, captured recombinant alpha-synuclein aggregates, specifically excluding monomers, at picomolar concentrations. BF-79-2 also captured alpha-synuclein aggregates in human blood. Replacing antibodies with small molecules as capturing agents on the SiMoA platform enhances the assay versatility, since small molecules can be screened in silico and synthesized without laborious molecular biology techniques. The application of small molecules as capturing agents broadens the capabilities of the SiMoA platform, rendering it more adaptable for biomarker discovery and disease diagnostics.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
A Novel Method for Detecting Protein Aggregates Using Plasmonic Sensing
Background: Amyloid‐beta (Aβ) protein aggregates have been implicated in the pathology of Alzheimer’s disease (AD). These aggregates are difficult to characterise due to their small size, requiring very sensitive techniques. Gold Nanoparticles (AuNPs) form plasmonic cavities when in close proximity to a gold surface. The cavity both enhances and scatters incident light, with a resonant wavelength strongly dependent on the size of the cavity. These plasmonic cavities were used to detect and size Aβ aggregates at ultra‐low concentration using darkfield spectroscopy.Methods: AuNPs were coated with the Aβ specific 6E10 capture antibody, incubated with a synthetic aggregate sample, and centrifuged to isolate the AuNPs. They were then placed on a gold surface, and darkfield scattering spectra were obtained. The peak scattering wavelengths for each AuNP were used to produce a histogram of gap sizes, and thus the size distribution of detected protein aggregates.Results: Significant differences were seen in resonant peak position between monomeric samples of Aβ and 24 hour aggregated samples. This allows for easy identification of protein monomer vs fibrillar aggregates. In the case of aggregates, some peaks in the darkfield scattering spectra also appeared strongly polarised, suggesting dimerisation of the AuNPs. This was not present for the case of monomeric sample.Conclusions: With this novel technique it was possible to clearly distinguish between samples of Aβ monomer and aggregates. This approach can likely be expanded to find the range and proportion of aggregate sizes in serum samples to detect the onset of AD. The AuNP dimerisation when Aβ aggregates are present is also interesting, and may serve as further verification of the size or shape of these aggregates.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessA Novel Method for Detecting Protein Aggregates Using Plasmonic Sensing
Background: Amyloid‐beta (Aβ) protein aggregates have been implicated in the pathology of Alzheimer’s disease (AD). These aggregates are difficult to characterise due to their small size, requiring very sensitive techniques. Gold Nanoparticles (AuNPs) form plasmonic cavities when in close proximity to a gold surface. The cavity both enhances and scatters incident light, with a resonant wavelength strongly dependent on the size of the cavity. These plasmonic cavities were used to detect and size Aβ aggregates at ultra‐low concentration using darkfield spectroscopy.Methods: AuNPs were coated with the Aβ specific 6E10 capture antibody, incubated with a synthetic aggregate sample, and centrifuged to isolate the AuNPs. They were then placed on a gold surface, and darkfield scattering spectra were obtained. The peak scattering wavelengths for each AuNP were used to produce a histogram of gap sizes, and thus the size distribution of detected protein aggregates.Results: Significant differences were seen in resonant peak position between monomeric samples of Aβ and 24 hour aggregated samples. This allows for easy identification of protein monomer vs fibrillar aggregates. In the case of aggregates, some peaks in the darkfield scattering spectra also appeared strongly polarised, suggesting dimerisation of the AuNPs. This was not present for the case of monomeric sample.Conclusions: With this novel technique it was possible to clearly distinguish between samples of Aβ monomer and aggregates. This approach can likely be expanded to find the range and proportion of aggregate sizes in serum samples to detect the onset of AD. The AuNP dimerisation when Aβ aggregates are present is also interesting, and may serve as further verification of the size or shape of these aggregates.
- Open Access
POLCAM: Instant molecular orientation microscopy for the life sciences
Current methods for single-molecule orientation localization microscopy (SMOLM) require optical setups and algorithms that can be prohibitively slow and complex, limiting the widespread adoption for biological applications. We present POLCAM, a simplified SMOLM method based on polarized detection using a polarization camera, that can be easily implemented on any wide-field fluorescence microscope. To make polarization cameras compatible with single-molecule detection, we developed theory to minimize field of view errors, used simulations to optimize experimental design, and developed a fast algorithm based on Stokes parameter estimation which can operate over 1000 fold faster than the state of the art, enabling near instant determination of molecular anisotropy. To aid in the adoption of POLCAM, we developed open-source image analysis software, and a website detailing hardware installation and software use. To illustrate the potential of POLCAM in the life sciences, we applied our method to study alpha-synuclein fibrils, the actin cytoskeleton of mammalian cells, fibroblast-like cells and the plasma membrane of live human T cells.
Open AccessPOLCAM: Instant molecular orientation microscopy for the life sciences
Current methods for single-molecule orientation localization microscopy (SMOLM) require optical setups and algorithms that can be prohibitively slow and complex, limiting the widespread adoption for biological applications. We present POLCAM, a simplified SMOLM method based on polarized detection using a polarization camera, that can be easily implemented on any wide-field fluorescence microscope. To make polarization cameras compatible with single-molecule detection, we developed theory to minimize field of view errors, used simulations to optimize experimental design, and developed a fast algorithm based on Stokes parameter estimation which can operate over 1000 fold faster than the state of the art, enabling near instant determination of molecular anisotropy. To aid in the adoption of POLCAM, we developed open-source image analysis software, and a website detailing hardware installation and software use. To illustrate the potential of POLCAM in the life sciences, we applied our method to study alpha-synuclein fibrils, the actin cytoskeleton of mammalian cells, fibroblast-like cells and the plasma membrane of live human T cells.
- Open Access
- 12 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (20)
Fast slow folding of an outer membrane porin
Significance: Outer membrane porins play a crucial role in processes as varied as energy production, photosynthesis, and nutrient transport. They act as the gatekeepers between a gram-negative bacterium and its environment. Understanding how these proteins fold and function is important in improving our understanding and control of these processes. Here we use single-molecule methods to help resolve the apparent differences between the fast folding expected on a molecular scale and the slow kinetics observed in ensemble measurements in the laboratory.
- 12 May 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (20)
Open AccessFast slow folding of an outer membrane porin
Significance: Outer membrane porins play a crucial role in processes as varied as energy production, photosynthesis, and nutrient transport. They act as the gatekeepers between a gram-negative bacterium and its environment. Understanding how these proteins fold and function is important in improving our understanding and control of these processes. Here we use single-molecule methods to help resolve the apparent differences between the fast folding expected on a molecular scale and the slow kinetics observed in ensemble measurements in the laboratory.